Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)
Standard BioTools Inc. (LAB)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced a recent paper published in Nature Scientific Reports, by researchers at Pfizer Research and Development, that detailed their use of the high-plex SomaScan® Assay, leveraging an industry-leading 7,000-protein biomarker panel to analyze blood serum samples from patients in a Phase 2a clinical trial for nonalcoholic fatty liver disease (NAFLD) and NASH. Nonalcoholic Fatty Liver Disease, or NAFLD, and nonalcoholic steatohepatitis (NASH) are becoming a global population health concern. Because diagnosing these diseases involves invasive liver biopsies, which can be challenging and expensive, many patients go untested and untreated. These diseases are complex in their impact on the liver, creating lipid accumulations, stiffness in the liver tissue, ballooning of the liver and chronic inflammation. In collaboration with major pharmaceutical companies and leading ac
Show less
Read more
Impact Snapshot
Event Time:
LAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LAB alerts
High impacting Standard BioTools Inc. news events
Weekly update
A roundup of the hottest topics
LAB
News
- Spatial Proteomics Market Projected to Reach USD 264.89 Million by 2032, Driven by a Strong 14.6% CAGR | Polaris Market Research [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Appoints Alex Kim as Chief Financial OfficerGlobeNewswire
- Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17 [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Inc. (NASDAQ: LAB) had its price target lowered by analysts at TD Cowen from $2.75 to $2.50. They now have a "buy" rating on the stock.MarketBeat
LAB
Earnings
- 10/30/24 - Beat
LAB
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- LAB's page on the SEC website